首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women
【2h】

A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women

机译:Maca根双盲安慰剂对照试验作为抗抑郁药诱发的女性性功能障碍的治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective. We sought to demonstrate that maca root may be an effective treatment for antidepressant-induced sexual dysfunction (AISD) in women. Method. We conducted a 12-week, double-blind, placebo-controlled trial of maca root (3.0 g/day) in 45 female outpatients (mean age of 41.5 ± 12.5 years) with SSRI/SNRI-induced sexual dysfunction whose depression remitted. Endpoints were improvement in sexual functioning as per the Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ). Results. 45 of 57 consented females were randomized, and 42 (30 premenopausal and 12 postmenopausal women) were eligible for a modified intent-to-treat analysis based on having had at least one postmedication visit. Remission rates by the end of treatment were higher for the maca than the placebo group, based on attainment of an ASEX total score ≤ 10 (9.5% for maca versus 4.8% for placebo), attaining an MGH-SFQ score ≤ 12 (30.0% for maca versus 20.0% for placebo) and reaching an MGH-SFQ score ≤ 8 (9.5% for maca versus 5.0% for placebo). Higher remission rates for the maca versus placebo group were associated with postmenopausal status. Maca was well tolerated. Conclusion. Maca root may alleviate SSRI-induced sexual dysfunction in postmenopausal women. This trial is registered with .
机译:目的。我们试图证明玛咖根可能是抗抑郁药诱发的女性性功能障碍(AISD)的有效治疗方法。方法。我们对45名患有SSRI / SNRI所致性功能障碍且抑郁得以缓解的女性门诊患者(平均年龄41.5±12.5岁)进行了为期12周,双盲,安慰剂对照的玛咖根(3.0μg/天)试验。终点是根据亚利桑那州性经验量表(ASEX)和马萨诸塞州综合医院性功能问卷(MGH-SFQ)进行的性功能改善。结果。在57位同意的女性中,有45位是随机分组的,其中42位(30位绝经前女性和12位绝经后女性)有资格进行修改后的意向治疗分析,其依据是至少接受过一次药物治疗后的随访。根据获得的ASEX总评分≤10(玛卡9.5%比安慰剂4.8%),MGH-SFQ得分≤12(30.0%),玛卡治疗结束时的缓解率高于安慰剂组。对于Maca,安慰剂为20.0%,而MGH-SFQ得分≤8(Maca为9.5%,安慰剂为5.0%)。与安慰剂组相比,玛卡组的缓解率更高与绝经后状态有关。玛卡耐受性良好。结论。玛咖根可以缓解绝经后妇女SSRI引起的性功能障碍。此试用版已在进行注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号